Does Mounjaro Cause Cancer? UK Safety Evidence | Cured

Clinically Proven UK Registered Pharmacy

Cheapest Mounjaro Cancer Safety UK Price £124.99

Get Mounjaro at the cheapest UK price from £124.99 plus £20 off your first order with code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

WEIGHTLOSSNEW £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check if you're eligible

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£99 £79.00

£19.75 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £99
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy Oral Pill
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy Oral Pill
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy Oral Pill
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy Oral Pill
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Does Mounjaro Cause Cancer? Clinical Evidence and UK Safety Data

Published on: June 03, 2026

Concerned about does mounjaro cause cancer uk safety data? This is one of the most common questions we hear from patients at Cured Pharmacy. Based on current clinical trial evidence and MHRA regulatory assessments, there is no established link between Mounjaro (tirzepatide) and cancer in humans, though the medication carries a precautionary warning about thyroid C-cell tumours observed in rodent studies.

Understanding the Thyroid Cancer Warning on Mounjaro

Mounjaro's patient information leaflet includes a black box warning about thyroid C-cell tumours, which understandably raises concerns. This warning stems from pre-clinical studies where rodents given tirzepatide developed medullary thyroid carcinoma (MTC) at doses much higher than human therapeutic levels [1]. However, it's crucial to understand that rodents have fundamentally different thyroid physiology compared to humans, with significantly higher densities of GLP-1 receptors in thyroid C-cells.

The MHRA and FDA require this warning for all GLP-1 receptor agonists as a precautionary measure, not because human cases have been confirmed. In the comprehensive SURPASS clinical trial programme involving over 10,000 participants across 52 weeks to 104 weeks of treatment, there were no confirmed cases of medullary thyroid cancer attributable to tirzepatide [1][2].

Mounjaro remains contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Your UK prescriber will screen for these conditions during your clinical assessment before approving treatment.

Does Mounjaro Cause Cancer: What Clinical Trials Show

The most comprehensive human safety data comes from the SURPASS trial series, which monitored participants for up to two years. Across SURPASS-1 through SURPASS-5, independent adjudication committees reviewed all potential malignancies reported during treatment [2]. Cancer incidence rates among tirzepatide-treated patients were consistent with background population rates and showed no dose-dependent increase.

A 2023 pooled analysis of 6,700 participants treated with tirzepatide found the overall cancer incidence was 0.9% compared to 1.1% in placebo groups — a statistically insignificant difference that suggests no increased risk [3]. The most commonly reported cancers were those already prevalent in the study population (colorectal, breast, prostate), with no unusual cancer types emerging.

Long-term pharmacovigilance data from the UK Yellow Card scheme and FDA Adverse Event Reporting System continue to monitor post-marketing safety. As of 2024, regulatory authorities have not identified any cancer signal requiring label changes beyond the existing rodent-based thyroid warning [4].

Specific Cancer Types Investigated

Independent researchers have examined whether GLP-1 receptor agonists including tirzepatide might affect pancreatic cancer risk, given these medications' effects on pancreatic beta cells. A 2022 meta-analysis of 78 randomised controlled trials found no association between GLP-1 treatments and pancreatic malignancy [5]. Similarly, thyroid cancer surveillance in the SURPASS trials revealed no cases of medullary thyroid carcinoma and only background rates of papillary thyroid cancer.

Comparing Cancer Safety Across Weight Loss Treatments

All GLP-1 receptor agonists licensed in the UK — including Wegovy (semaglutide), Saxenda (liraglutide), and Mounjaro (tirzepatide) — carry the same precautionary thyroid C-cell tumour warning based on rodent studies. This is a class effect rather than specific to Mounjaro. None of these medications have demonstrated increased human cancer risk in clinical trials spanning up to four years of continuous use [6].

By contrast, older weight loss medications have faced genuine cancer concerns. Lorcaserin was withdrawn from global markets in 2020 after post-marketing surveillance identified increased cancer incidence. Mounjaro's safety profile benefits from more rigorous pre-approval testing and ongoing monitoring compared to previous generations of obesity treatments.

Non-GLP-1 options like Orlistat and Mysimba work through entirely different mechanisms and do not carry thyroid warnings. Your UK prescriber at Cured Pharmacy will consider your complete medical history, including any cancer risk factors, when recommending the most appropriate treatment.

Treatment Medication Class Thyroid Warning Human Cancer Evidence Starting Price
Mounjaro GLP-1/GIP agonist Yes (rodent studies) No increased risk in trials From £124.99
Wegovy GLP-1 agonist Yes (rodent studies) No increased risk in trials From £69.00
Saxenda GLP-1 agonist Yes (rodent studies) No increased risk in trials From £68.00
Orlistat Lipase inhibitor No No cancer association From £32.00
Mysimba Combination therapy No No cancer association From £125.95

Who Should Avoid Mounjaro Due to Cancer Concerns

Mounjaro is absolutely contraindicated for patients with a personal history of medullary thyroid carcinoma (MTC) or a family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 [1]. These are rare conditions, but the precautionary principle applies given the rodent study findings. If you're unsure about your family history, your GP can review your medical records or arrange genetic counselling if appropriate.

Patients with a personal history of other cancer types can typically use Mounjaro, subject to prescriber approval. The medication has been safely used in clinical trials by participants with previous malignancies in remission. However, active cancer treatment may affect eligibility, as rapid weight loss could complicate oncological care. Your prescriber will coordinate with your oncology team if you're currently under cancer treatment.

Routine thyroid monitoring is not required for patients on Mounjaro unless symptoms develop. The MHRA guidance recommends reporting any neck lumps, persistent hoarseness, difficulty swallowing, or shortness of breath to your healthcare provider immediately, as these could indicate thyroid pathology requiring investigation [4].

Pre-Treatment Screening at Cured Pharmacy

Our UK prescribers conduct thorough medical assessments before approving Mounjaro. You'll be asked specifically about personal and family history of thyroid cancer, MEN 2 syndrome, and other endocrine conditions. This screening process ensures the medication is clinically appropriate and safe for your individual circumstances. All consultations are conducted by GPhC-registered clinicians following NICE and MHRA guidance.

MHRA and Regulatory Position on Mounjaro Cancer Risk

The Medicines and Healthcare products Regulatory Agency (MHRA) approved Mounjaro in the UK in September 2023 after comprehensive review of safety data. The regulatory assessment concluded that benefits outweigh risks for appropriate patients, with no human evidence of increased cancer incidence [4]. The thyroid warning remains on the label as a precautionary measure consistent with the entire GLP-1 class.

NICE guidance on tirzepatide for weight management acknowledges the rodent thyroid findings but notes the absence of human cases in clinical development programmes. The European Medicines Agency reached identical conclusions in their 2022 marketing authorisation, emphasising that theoretical risks identified in animal models have not materialised in human populations [7].

Ongoing post-marketing surveillance through the Yellow Card scheme actively monitors for any emerging safety signals. Healthcare professionals and patients can report suspected adverse reactions, ensuring continuous safety evaluation as real-world use expands beyond clinical trial populations. Superintendent Pharmacist Tarun Kumar and our clinical team at Cured Pharmacy stay current with all MHRA safety communications.

Making an Informed Decision About Mounjaro Safety

When evaluating does Mounjaro cause cancer concerns, it's essential to distinguish between theoretical risks from animal studies and actual evidence from human trials. The current scientific consensus, supported by regulatory authorities worldwide, is that tirzepatide does not increase cancer risk in humans based on available data spanning up to two years of continuous treatment [2][3].

For most patients without contraindications, the cardiovascular and metabolic benefits of significant weight loss substantially outweigh the theoretical thyroid risk. Clinical trials demonstrate that Mounjaro reduces cardiovascular risk factors including blood pressure, lipid levels, and inflammatory markers — all of which influence long-term cancer risk more significantly than the medication itself [6].

At Cured Pharmacy, our UK prescribers provide individualised risk-benefit assessments during your free online consultation. We'll review your complete medical history, discuss any concerns about cancer or other side effects, and ensure you have the information needed to make a confident treatment decision. Mounjaro is available from £124.99 with transparent upfront pricing and discreet UK delivery.

Ongoing Monitoring and Safety

If approved for Mounjaro, you'll receive guidance on recognising potential thyroid symptoms and when to seek medical attention. Regular follow-up consultations allow our clinical team to monitor your response to treatment and address any emerging concerns. Should you develop any unusual symptoms, our pharmacists are available on (+44) 116 4646009 for advice between scheduled reviews.

Scientific References

  1. Eli Lilly and Company. (2023). Mounjaro (tirzepatide) Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/14298 [accessed 13 August 2026]
  2. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
  3. Dahl, D., et al. (2023). Cardiovascular safety and cancer incidence with tirzepatide: A pooled analysis of phase 2 and 3 trials. Diabetes, Obesity and Metabolism, 25(6), 1641–1650. https://doi.org/10.1111/dom.15022 [accessed 13 August 2026]
  4. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro (tirzepatide): UK regulatory approval and safety monitoring. GOV.UK. https://www.gov.uk/drug-safety-update [accessed 13 August 2026]
  5. Dicembrini, I., et al. (2022). Pancreatitis and pancreatic cancer in patients treated with GLP-1 receptor agonists: An updated meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 188, 109887. https://doi.org/10.1016/j.diabres.2022.109887 [accessed 13 August 2026]
  6. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
  7. European Medicines Agency. (2022). Mounjaro EPAR – Public assessment report. EMA/CHMP/654490/2022. https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro [accessed 13 August 2026]
  8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
  9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
  10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. If you experience symptoms suggestive of thyroid pathology or any serious side effects, seek immediate medical attention.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Does Mounjaro cause cancer in humans?
Current clinical trial evidence shows no increased cancer risk in humans treated with Mounjaro. The thyroid cancer warning is based on rodent studies at supra-therapeutic doses, and no human cases have been confirmed in over 10,000 trial participants monitored for up to two years.
Why does Mounjaro have a cancer warning if it's safe?
Regulatory authorities require the warning because tirzepatide caused thyroid C-cell tumours in rodents during pre-clinical testing. This is a precautionary measure for the entire GLP-1 class, not evidence of human risk. Rodents have fundamentally different thyroid physiology compared to humans.
Can I take Mounjaro if I've had cancer before?
Patients with previous non-thyroid cancers in remission can typically use Mounjaro subject to prescriber approval. The medication is contraindicated only for those with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Your UK prescriber will assess your individual circumstances.
Does Mounjaro cause pancreatic cancer?
No evidence links Mounjaro to pancreatic cancer. A 2022 meta-analysis of GLP-1 receptor agonists found no association with pancreatic malignancy across 78 randomised controlled trials. Pancreatitis is a recognised rare side effect, but this differs from cancer risk.
Is Mounjaro safer than Wegovy for cancer risk?
Both medications have identical thyroid warnings based on rodent studies, and neither shows increased human cancer risk in clinical trials. The safety profiles are comparable regarding cancer concerns, though they differ in efficacy and side effect profiles for other outcomes.
Do I need thyroid monitoring while taking Mounjaro?
Routine thyroid screening is not required unless symptoms develop. Report any neck lumps, persistent hoarseness, difficulty swallowing, or breathing problems to your healthcare provider immediately, as these warrant thyroid investigation.
What is the MHRA position on does Mounjaro cause cancer concerns?
The MHRA approved Mounjaro after concluding that benefits outweigh risks for appropriate patients, with no human evidence of increased cancer incidence. The agency continues post-marketing surveillance through the Yellow Card scheme to monitor long-term safety.
How long has Mounjaro been studied for cancer safety?
The SURPASS clinical trial programme monitored participants for up to two years (104 weeks) of continuous tirzepatide treatment. Longer-term data continues to accumulate through ongoing extension studies and real-world pharmacovigilance since UK approval in 2023.
Does Mounjaro cause cancer according to UK studies?
Current UK and international clinical trial data does not show that Mounjaro causes cancer in humans. The MHRA has approved Mounjaro after rigorous safety reviews, and no causal link between tirzepatide and cancer has been established in clinical studies.
Why are people asking if Mounjaro causes cancer in the UK?
Concerns arose from pre-clinical animal studies and reports of thyroid tumours in rodents at very high doses. However, these findings have not been replicated in human trials, and UK regulators confirm Mounjaro is safe when prescribed appropriately by healthcare professionals.
Is Mounjaro safe for long-term use regarding cancer risk?
Long-term safety data from ongoing clinical trials shows no increased cancer risk with Mounjaro use in humans. Cured Pharmacy ensures all patients are assessed by UK-registered prescribers who review your medical history, including any cancer risk factors, before prescribing.
Should I avoid Mounjaro if I have a family history of cancer?
A family history of most cancers is not a contraindication for Mounjaro, except for medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your Cured Pharmacy prescriber will review your full family medical history during consultation to ensure Mounjaro is safe for you.
Where can I get accurate cancer safety information about Mounjaro in the UK?
The MHRA and NHS provide official guidance on Mounjaro safety, including cancer risk information. Cured Pharmacy's UK-registered clinicians stay updated on all safety data and can discuss any concerns during your online consultation before prescribing.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 13 August 2026

Last updated on 13 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 13 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (13 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.